ly 300502 has been researched along with terazosin in 1 studies
| Studies (ly 300502) | Trials (ly 300502) | Recent Studies (post-2010) (ly 300502) | Studies (terazosin) | Trials (terazosin) | Recent Studies (post-2010) (terazosin) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 658 | 173 | 104 |
| Protein | Taxonomy | ly 300502 (IC50) | terazosin (IC50) |
|---|---|---|---|
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 6.042 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.011 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.005 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
1 review(s) available for ly 300502 and terazosin
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |